Aoti

Aoti Long-term Debt

The Long-Term Debt of Aoti (AOTI.L) as of Oct 30, 2026 is 8.43 M USD. In the previous year, Long-Term Debt was 11.70 M USD — a change of -27.89% (lower).

Long-term Debt

8.43 MUSD

YoY

-27.89%

Last updated:

Long-Term Debt of Aoti is 2024 8.43 M USD. Long-Term Debt of Aoti was 2023 11.70 M USD. It decreases by -27.89% lower compared to the previous year.

The Aoti Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2021
0.00 USD
Jan 1, 2022
11.60 M USD
Jan 1, 2023
11.70 M USD
Jan 1, 2024
8.43 M USD
The Aoti Long-term Debt history
YEARLong-term DebtYoY
8.43 MUSD-27.89%
11.70 MUSD+0.83%
11.60 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aoti Stock analysis

What does Aoti do? Aoti Inc generates revenue through its wound care technology products, primarily TWO2 therapy and NEXA Negative Pressure Wound Therapy (NPWT). The company's TWO2 therapy solutions include TWO2 Extremity Chamber and TWO2 Multi-Patch, designed for patient-administered treatment of chronic wounds. NEXA NPWT System is a disposable, multi-week solution for wound care, targeting healthcare providers who manage chronic wound cases. Aoti focuses on enhancing access to care and improving clinical outcomes for patients with chronic conditions, leveraging robust clinical evidence to support its products' safety and efficacy. Healthcare providers and institutions purchasing TWO2 and NEXA systems form the primary customer segment, driven by the need for clinically proven wound care solutions. The company's products are positioned to address chronic wound management globally, with emphasis on patient quality of life and health equity. Aoti's business model centers on delivering evidence-based therapies that improve patient outcomes while meeting healthcare systems' demands for effective, efficient care delivery. The company's revenue streams are derived from direct sales of TWO2 and NEXA systems to healthcare facilities and practitioners. Product offerings are structured to support both acute and chronic wound care needs, with TWO2 being a multi-modality patient-administered therapy and NEXA providing a flexible, disposable NPWT system. Aoti's focus on clinical evidence ensures its solutions align with healthcare providers' requirements for safety and efficacy in wound treatment. Aoti is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aoti stock

Long-Term Debt of Aoti is 8.43 M USD in 2024.

Long-Term Debt of Aoti changed from 11.70 M USD to 8.43 M USD, representing a -27.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Aoti since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Aoti historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aoti

All Key Metrics — Aoti